Hormonal
GLP-1 receptor agonists (e.g., liraglutide, semaglutide) resolve MASH histology primarily through substantial weight loss and improved insulin resistance, rather than direct hepatocyte effects.
GLP-1 agonists like semaglutide and liraglutide are effective treatments for MASH, but their primary benefit comes from the weight loss and metabolic improvements they induce, not a direct 'liver cure.' Expect significant weight loss (often 10-15%+), but also manage expectations regarding side effects like nausea, which are common initially. These drugs resolve MASH in a majority of patients but may not reverse advanced fibrosis as effectively. Consult a specialist to determine if the benefits outweigh the burden of injection and side effects for your specific liver stage.
Any effect of GLP1 agonists on MASH is therefore likely to be indirect and may be related to a reduction in calorie intake, body weight and insulin resistance, all of which lead to reduced liver lipid accumulation and hepatic inflammation.
Why this rating
Supported by multiple Phase IIb/III clinical trials (LEAN, SEMA-NASH) showing histological resolution, though fibrosis improvement is less consistent.
Source
Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver
Philip N. Newsome et al. · Journal of Hepatology · 2023
DOI 10.1016/j.jhep.2023.07.033
More from this paper
- Dual GLP-1/glucagon agonists (e.g., cotadutide, pemvidutide) provide greater reductions in liver fat and fibrosis markers than GLP-1 mono-agonists, likely due to glucagon-mediated mitochondrial turnover and glycogenolysis.Moderate
- The optimal ratio of GLP-1 to glucagon/GIP agonism in combination therapies is unknown, and the balance between efficacy (liver fat reduction) and safety (hyperglycemia, side effects) remains a key challenge.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →